Costs and clinical outcomes of patients with diffuse large B-cell lymphoma in first remission: role of PET/CT surveillance
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: The role of [18F]-f luorodeoxyglucose positron emission tomography- computed tomography (PET/CT) in patients with diffuse large B-cell lymphoma (DLBCL) in first remission is unclear. Methods: Medical costs within the first 3 years of treatment completion and clinical outcomes of 118 patients with DLBCL in first remission with and without surveillance PET/CT (PET/CT [+] group [n = 76] and PET/CT [–] group [n = 42], respectively) were retrospectively analyzed. Results: In a propensity matched cohort with adjustment for International Prognostic Index risk and relapse, the PET/CT (+) group was shown to have similar medical costs as the PET/CT (–) group. Relapse-free survival (RFS) and overall survival (OS) were comparable between the two groups (median RFS not reached [NR] for both groups, p = 0.133; median OS NR, p = 0.542). Among 76 patients with surveillance PET/CT, 31 (40.8%) had findings suggestive of recurrence and 16 of these (51.6%) were later confirmed to have recurrent disease. Fifteen patients (48.4%) were confirmed to not have recurrence after follow-up CT or PET/CT evaluation (n = 10) and biopsy (n = 4). None of the patients with negative PET/CT findings had disease recurrence. Sensitivity, specificity, positive predictive value, and negative predictive value of PET/CT for detection of recurrence were 1, 0.75, 0.52, and 1, respectively. Conclusions: Surveillance PET/CT resulted in similar clinical outcomes and medical costs compared to no surveillance PET/CT. Approximately half of patients with PET/CT findings of recurrence had no recurrence after follow-up imaging and biopsy, which would not have been carried out if PET/CT had not been performed in the first place.
Abstract
Background/Aims: The role of [18F]-f luorodeoxyglucose positron emission tomography- computed tomography (PET/CT) in patients with diffuse large B-cell lymphoma (DLBCL) in first remission is unclear. Methods: Medical costs within the first 3 years of treatment completion and clinical outcomes of 118 patients with DLBCL in first remission with and without surveillance PET/CT (PET/CT [+] group [n = 76] and PET/CT [–] group [n = 42], respectively) were retrospectively analyzed. Results: In a propensity matched cohort with adjustment for International Prognostic Index risk and relapse, the PET/CT (+) group was shown to have similar medical costs as the PET/CT (–) group. Relapse-free survival (RFS) and overall survival (OS) were comparable between the two groups (median RFS not reached [NR] for both groups, p = 0.133; median OS NR, p = 0.542). Among 76 patients with surveillance PET/CT, 31 (40.8%) had findings suggestive of recurrence and 16 of these (51.6%) were later confirmed to have recurrent disease. Fifteen patients (48.4%) were confirmed to not have recurrence after follow-up CT or PET/CT evaluation (n = 10) and biopsy (n = 4). None of the patients with negative PET/CT findings had disease recurrence. Sensitivity, specificity, positive predictive value, and negative predictive value of PET/CT for detection of recurrence were 1, 0.75, 0.52, and 1, respectively. Conclusions: Surveillance PET/CT resulted in similar clinical outcomes and medical costs compared to no surveillance PET/CT. Approximately half of patients with PET/CT findings of recurrence had no recurrence after follow-up imaging and biopsy, which would not have been carried out if PET/CT had not been performed in the first place.
참고문헌 (15)
- Held G, "Dose-intensified treatment of advanced-stage diffuse large B-cell lymphomas", Semin Hematol, 43, pp.221~229 (2006)
- Sehn LH, "Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia", J Clin Oncol, 23, pp.5027~5033 (2005)
- Pfreundschuh M, "CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma : 6-year results of an open-label randomised study of the MabThera International Trial(MInT)Group", Lancet Oncol, 12, pp.1013~1022 (2011)
- Feugier P, "Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma : a study by the Groupe d’Etude des Lymphomes de l’Adulte", J Clin Oncol, 23, pp.4117~4126 (2005)
- Hagberg H, "Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study", Ann Oncol, (17Suppl 4), pp.iv31~iv32 (2006)
- Johnson SA, "Imaging for staging and response assessment in lymphoma", Radiology, 276, pp.323~338 (2015)
- fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma, "J Clin Oncol", 2009, 1781~1787
- Petrausch U, "Risk-adapted FDG-PET", CT-based follow-up in patients with diffuse large B-cell lymphoma after first-line therapy, 2010, pp.21, 1694~1698
- Abel GA, "High rates of surveillance imaging for treated diffuse large B-cell lymphoma : findings from a large national database", Leuk Lymphoma, 53, pp.1113~1116 (2012)
- Thompson CA, "Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma", J Clin Oncol, 32, pp.3506~3512 (2014)
- Long NM, "Causes and imaging features of false positives and false negatives on F-PET", CT in oncologic imaging, 2011, pp.2, 679~698
- Zelenetz AD, "Non-Hodgkin’s lymphomas, version 2.2014", J Natl Compr Canc Netw, 12, pp.916~946 (2014)
- Cheson BD, "Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma : the Lugano classification", J Clin Oncol, 32, pp.3059~3068 (2014)
- Tilly H, "Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up", Ann Oncol, (26 Suppl 5), pp.v116~v125 (2015)
- Huntington SF, "Cost-effectiveness analysis of routine surveillance imaging of patients with diffuse large B-cell lymphoma in first remission", J Clin Oncol, 33, pp.1467~1474 (2015)